Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Glenmark Expects ‘Strong Year’ With ‘First’ EU Spiriva Rival Imminent

Signed Licensing Deal For Tiotropium Bromide In 2018

Executive Summary

Glenmark said it would continue to deliver new respiratory products in Europe moving forward as the Indian firm lines up what it believes will be the first generic version of Boehringer Ingelheim’s Spiriva Handihaler.

You may also be interested in...

Glenmark’s Ryaltris To Reach Western Europe Following Approvals

Glenmark is toasting another launch for the company’s Ryaltris novel treatment for allergic rhinitis, this time with plans to roll the product out in 17 countries across western Europe.

FDA Publishes 69 Product-Specific Guidances

The FDA has issued 69 product-specific guidances for generic drug development, comprising 26 new guidances and 43 revised documents.

Glenmark inks a deal for Spiriva in Europe

Glenmark is aiming to bolster its burgeoning respiratory presence in Europe by signing an exclusive licensing and marketing agreement with an undisclosed third party for a generic of Boehringer Ingelheim’s Spiriva Handihaler (tiotropium bromide) dry-powder inhaler in Western European markets.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts